logo

For the Inventor, By the Inventor

Gales Ferry, CT, United States of America

John P Dirlam

This inventor holds 22 USPTO granted patents, primarily in Antibiotic Development. Top assignee: Pfizer Corporation. Active years: 1976-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John P Dirlam. Retrieved from https://idiyas.com/inventor/john-p-dirlam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22

% Patents Active = 95.5

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 52(Granted Patents)


Location History:

  • New London, CT (US) (1977)
  • Gales Ferry, CT (US) (1976 - 2006)

Company Filing History:

goldMedal22 out of 4,488 
 
Pfizer Corporation
 patents

Years Active: 1976-2006

Loading Chart...
Areas of Expertise:
Macrolides
Polycyclic Ether
Antibiotics
Azalides
Anticoccidial
Growth Promoting
Quinoxaline
2-Amino-Oxazolinones
Antibacterial
Dioxides
Anthelmintic
Microorganism
22 patents (USPTO):Explore Patents
1. 7015203 - Macrolides (2006-03-21),
2. 6472371 - Macrolides (2002-10-29),
3. 6329345 - 13-membered azalides and their use as antibiotic agents (2001-12-11),
4. 6270768 - Azalides and methods of making same (2001-08-07),
5. 5965445 - Polycyclic ether antibiotic having anthelmintic, anticoccidial and (1999-10-12),
6. 5891727 - Acidic polycyclic ether useful as an anticoccidial agent and as a growth (1999-04-06),
7. 5494931 - Acidic polycyclic ether antibiotic (1996-02-27),
8. 5478735 - Process for producing acidic polycyclic ether antibiotic having (1995-12-26),
9. 5418152 - Acidic polycyclic ether antibiotic (1995-05-23),
10. 5403738 - Microorganism for producing polycyclic ether antibiotics (1995-04-04),
11. 5350764 - Anticoccidial and growth promoting polycyclic ether antibiotic (1994-09-27),
12. 5298524 - Acidic polycyclic ether antibiotic having an anticoccidial and growth (1994-03-29),
13. 5206263 - Acidic polycyclic ether useful as an anticoccidial agent and as a growth (1993-04-27),
14. 5158937 - Acidic polycyclic ether antibiotic having anticoccidial and growth (1992-10-27),
15. 5155097 - Polycyclic ether antibiotic having anthelmintic, anticoccidial and (1992-10-13),

Title: John P. Dirlam: Innovator in Antibacterial Compounds

Introduction: John P. Dirlam, based in Gales Ferry, Connecticut, is a prominent inventor with a remarkable portfolio of 22 patents. His contributions to the field of pharmaceuticals, particularly in the development of antibacterial agents, have had a significant impact on the treatment of bacterial and protozoa infections.

Latest Patents: Among his notable inventions, John Dirlam's latest patents focus on novel erythromycin analogs and azalides, specifically emphasizing compounds with innovative C-13 substituents. These compounds are designed to be pharmaceutically acceptable salts that serve as effective antibacterial agents. The invention includes pharmaceutical compositions that incorporate these compounds, alongside methods for treating various bacterial and protozoa infections. Furthermore, his work details processes for preparing these compounds and highlights intermediates that are essential for their synthesis.

Career Highlights: John Dirlam has established a career at Pfizer Corporation, where he has contributed extensively to research and development in the pharmaceutical industry. His expertise in creating compounds that address complex medical challenges showcases his innovative spirit. With 22 patents to his name, he stands out as a key figure in advancing therapeutic options.

Collaborations: Throughout his career, John Dirlam has worked alongside esteemed colleagues, including Hiroshi Maeda and Junsuke Tone. These collaborations illustrate the importance of teamwork in driving innovation and enhancing the efficacy of pharmaceutical developments.

Conclusion: John P. Dirlam is a noteworthy inventor whose work at Pfizer Corporation continues to influence the field of pharmaceuticals significantly. His commitment to innovation in antibacterial agents not only demonstrates his expertise but also highlights the potential for advancements in treating infections and improving public health. With an impressive array of patents, Dirlam's contributions will undoubtedly shape the future of therapeutic interventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…